Pelvic Inflammatory Disease
0 original drugsPelvic Inflammatory Disease has 0 FDA-approved novel treatments across 1 drug target. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Pelvic Inflammatory Disease Clinical Pipeline by Phase
2 industry-sponsored trials across 2 sponsors
Novel Pelvic Inflammatory Disease Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (5 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Pelvic Inflammatory Disease Drug Targets
Molecular targets of approved and investigational Pelvic Inflammatory Disease drugs — 1 target tracked.
Generic Drugs (8 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs